retatrutide type 2 diabetes Eli Lilly's Shows Promise in Obesity, and Cardiovascular Risk Factors | Graham Sanders posted on the topic New Triple-Action Drug Retatrutide Shows

GLP-1 agonism: Reduces appetite, slows gastric emptying, promotes satiety GIP agonism: Enhances insulin secretion, may reduce GLP-1-related nausea Glucagon agonism: Increases hepatic glucose output control, drives thermogenesis and energy expenditure Phase 2 clinical trial data published in 2023 showed subjects lost an average of 24.2% of body weight over 48 weeks making it arguably the most potent weight-loss compound currently known

Include fats from sources like avocado, nuts, olive oil, and fatty fish

Dopamine analogs and somatostatin analogs (SSAs) have been used for medical adjuvant therapies to suppress excessive Gs signaling as activating the Gi/o-coupled dopamine 2 receptor (D2R) or SSTRs, respectively 14

Increased energy expenditure : Semaglutide can increase the bodys metabolism, leading to an increase in energy expenditure and a decrease in body weight